Analysts think CRVS stock price could increase by 88%
Nov 09, 2025, 12:25 PM
12.97%
What does CRVS do
Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company based in Burlingame, California, develops immune modulators for cancers and autoimmune diseases, with key products including soquelitinib and ciforadenant. Founded in 2016, it employs 28 people and focuses on innovative immunotherapy approaches.
8 analysts think CRVS stock price will increase by 88.02%. The current median analyst target is $14.28 compared to a current stock price of $7.59. The lowest analysts target is $11.11 and the highest analyst target is $25.20.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.